Future Research · AI Research Agents

High-Throughput

AI Research Agents

for Life Sciences & Biotech

See It Work Beta Login
Enterprise-grade research infrastructure · Early access by selection
See It In Action
futureresearch.ai / lit-agent
See full case study →
Knowledge Graph
0 authentic
0 noise
0 insights
Agent Reasoning
10,000+Publications Analyzed
·
7Agent Steps
·
44M+PubMed Sources
·
HoursNot Months
The Shift

Lean teams.
Disproportionate output.

"The next generation of life sciences companies won't have larger R&D departments. They'll have smaller teams running high-throughput AI agents — and they'll out-research organizations ten times their size."

Research, legal, and product teams already spend 60–70% of their time on information retrieval and synthesis. AI agents absorb that work entirely — freeing your team for judgment, strategy, and execution.

  • → R&D teams that complete systematic reviews in hours instead of hiring additional analysts.
  • → IP teams that screen patent landscapes without six-figure outside counsel engagements.
  • → Product teams that understand real user behavior across 100K+ data points — not survey samples.
  • → Organizations where every function operates on deep, current intelligence — continuously.
Life-Science Intelligence

An AI that understands
life sciences concepts.

Beyond search, Future Research structurally reasons over concepts, mechanisms, and outcomes.

  • → Converts findings from any paper into linked biological concepts instead of isolated snippets.
  • → Keeps compounds, pathways, biomarkers, and outcomes in one living graph that updates with every new signal.
  • → Uses proprietary concept-based reasoning to infer mechanism-level relationships most LLM tools and generic agents miss.
Symbiotic Concept Graph Proprietary reasoning layer
Findings Concepts Mechanisms Outcomes study signal clinical finding shared concept reasoning bridge inferred relation
concept-aware graph memory mechanism-level linking agentic synthesis beyond retrieval
Three Agents, Three Disciplines

Each agent is purpose-built
for a specific research domain.

Enterprise-grade analysis across scientific literature, patent filings, and real-world user data. Each agent operates at a scale and depth that manual processes cannot match.

⬡
Literature Research Agent

Systematic reviews, evidence synthesis, mechanism-of-action mapping, and clinical data extraction across 10,000+ publications per task — with full citation trails and structured knowledge graphs.

Future Research
10,000+
Typical tools
~100
Output: Complete systematic review with evidence grades, knowledge graph, and traceable citations.
◆
User Research Agent

Ingests 100K+ user-generated data points from reviews, forums, social media, and support threads. Filters out marketing, sponsored content, and spam. Surfaces authentic user behavior, intent signals, and unmet needs.

Data ingested
100K+
Noise removed
~70%
Output: Behavior cluster map, unmet needs analysis, authentic sentiment deep-dive — marketing noise excluded.
◈
Patent Intelligence Agent

Landscape analysis, freedom-to-operate screening, prior art search, and claims mapping across thousands of patents. Identifies prophetic examples and low-quality filings. Reduces outside counsel dependency by 40–60%.

Agent analysis
Hours
Outside counsel
4-8 wks
Output: Patent landscape map, FTO risk assessment, prior art report with blocking claims identified.
How It Works

From question
to intelligence.

Define your research target. Our agents plan, execute, and synthesize — transparently at every step.

01
Decompose
Expert research plan
→
02
Ingest
10K+ sources screened
→
03
Extract
Key findings & signals
→
04
Map
Knowledge graph
→
05
Analyze
Cross-reference & grade
→
06
Report
Decision-ready output
→
07
Interact
Chat with your data
Industries

Purpose-built for
life sciences and biotech.

Where research depth, IP strategy, and evidence quality are not optional — they are the operating system of the business.

Biotech & Pharma Nutritional Supplements Cosmetics & Skincare Medtech & Devices Applied Sciences
  • →
    Systematic Literature Review10,000+ papers analyzed per task. Evidence maps with mechanism and outcome data. Full citation provenance.
  • →
    Patent Landscape & FTOThousands of patents screened. Claims mapped against your technology. Freedom-to-operate risks flagged with supporting prior art.
  • →
    Real-World User Intelligence100K+ authentic user posts analyzed. Marketing and sponsored content filtered out. Behavioral patterns and unmet needs surfaced.
  • →
    Clinical Data ExtractionHundreds of trials structured and compared. Endpoints, populations, effect sizes — organized for regulatory and R&D decisions.
  • →
    Competitive Technical IntelligenceCross-reference competitor patents, publications, and user feedback to map their R&D direction and product trajectory.
Early Access

For teams that
intend to lead.

We partner with life sciences and biotech companies ready to lead their category — powered by AI agents that turn lean teams into research powerhouses.

Applied life sciences only · Early access by selection

For further inquiries, contact us (fed@futureresearch.ai)
✦
Request received.
We review every application. Expect to hear from us within 48 hours.
Literature Research Agent — Case Study
Evidence Synthesis:
Ginkgo Biloba Active Compounds
Customer intent: Memory Optimization — Identify all active compounds, grade clinical evidence for cognitive benefit, map synergies and interactions.
5,247
Papers Analyzed
312
Compounds Identified
47
Clinical Trials (RCTs)
8
Mechanisms Mapped
Top Active Compounds — Confidence Score for Memory Optimization
CompoundPapersRCTsMechanismConfidence
EGb 761 (standardized extract)1,84723Cerebral blood flow ↑, antioxidant
94%
Bilobalide4128Neuroprotection, mitochondrial function
89%
Ginkgolide B3877PAF antagonist, anti-inflammatory
86%
Ginkgolide A2985PAF antagonist, vascular protection
78%
Quercetin1,2034Antioxidant, anti-inflammatory (NF-κB)
72%
Kaempferol6343Neuroprotection, BDNF modulation
68%
Isorhamnetin1892Anti-inflammatory, BBB permeability
61%
Ginkgolide C941PAF antagonist (weaker)
42%
Ginkgolic Acid2670Cytotoxic — must be removed
8%
Proanthocyanidins1561Vascular tone, antioxidant
55%
Confidence score reflects strength of clinical evidence for memory optimization intent specifically. Compounds with high general evidence but weak cognitive data score lower.
Knowledge Graph: Synergies & Interaction Alerts

The agent's knowledge graph automatically identified compound–compound interactions by analyzing co-occurrence patterns, shared pathway targets, and clinical interaction reports across 5,247 papers.

⬡
Ginkgolide B + Bilobalide → Enhanced Neuroprotection
Co-administration shows 34% greater neuroprotective effect than either compound alone (n=6 preclinical studies, n=2 RCTs). Mechanism: complementary action on mitochondrial membrane potential + PAF inhibition.
SYNERGY CONFIRMED · Level I-B Evidence
⬡
EGb 761 + Phosphatidylserine → Additive Cognitive Benefit
Combined supplementation improved MMSE scores by 2.4 points vs. 1.1 points for EGb 761 alone in mild cognitive impairment patients (n=3 RCTs, 847 participants).
SYNERGY CONFIRMED · Level I-B Evidence
⬡
Quercetin + Kaempferol → Synergistic NF-κB Suppression
Both flavonoids target NF-κB pathway via different upstream regulators (IκB kinase vs. MAPK). Combined effect on neuroinflammation markers exceeds individual contributions by ~28%.
EMERGING SIGNAL · Level II-B Evidence
⚠
EGb 761 + Warfarin → Bleeding Risk Increase
Ginkgolide B is a potent PAF antagonist with antiplatelet activity. Co-administration with warfarin or other anticoagulants increases bleeding risk. 14 case reports, 3 systematic reviews documenting adverse events.
SIDE EFFECT ALERT · Contraindication
⚠
Ginkgolic Acid >5 ppm → Cytotoxicity / Allergenic
Ginkgolic acids are alkylphenols with demonstrated mutagenic and allergenic properties. European Pharmacopoeia limits to ≤5 ppm. Products exceeding this threshold show dose-dependent cytotoxicity in 8 studies.
SAFETY ALERT · Formulation Constraint
⚠
Ginkgo + SSRIs → Serotonin Syndrome Risk (Low)
Theoretical risk via MAO inhibition properties of ginkgo flavonoids. 4 case reports exist but causality is uncertain. Agent flagged as requires monitoring, not contraindication.
MONITOR · Level IV Evidence
Evidence Grade Distribution — Memory Optimization Claims
Level I-A (Meta-analysis)
23
14%
Level I-B (Large RCT)
29
18%
Level II-A (Small RCT)
36
22%
Level II-B (Cohort)
39
24%
Level III (Case-control)
20
12%
Level IV (Case series)
16
10%
163 total evidence items graded. 32% at Level I (strong clinical evidence). Agent auto-excluded 4,891 non-clinical papers from grading.
User Research Agent — Case Study
Real-World User Intelligence:
Magnesium Supplements Market
Objective: Aggregate authentic consumer experiences across all major platforms, filter out marketing noise, and generate actionable intelligence on behavior patterns, unmet needs, and switching triggers.
147,832
Data Points Collected
31%
Noise Filtered Out
101,849
Authentic Posts
6
Behavior Clusters
Data Source Breakdown
📦
Amazon Reviews
68,421 reviews · 46.3%
💬
Reddit Discussions
34,218 posts · 23.1%
🐦
Twitter / X Posts
21,847 posts · 14.8%
📷
Instagram Shares
14,502 posts · 9.8%
🌍
Health Forums (iHerb, Examine)
6,891 posts · 4.7%
📝
YouTube Comments
1,953 comments · 1.3%
Noise Filtering Pipeline

The agent applies multi-layer filtering to remove non-authentic content before analysis. Each layer uses distinct detection models trained on labeled datasets of marketing, bot, and incentivized content.

Raw data collected
147,832
✗ Marketing / promotional
−21,096
✗ Bot-generated / fake
−11,383
✗ Incentivized reviews
−7,102
✗ Sponsored / soft-ads
−6,402
✓ Authentic posts
101,849
31% of collected data was non-authentic. Instagram had the highest noise rate (62% filtered). Reddit had the lowest (11% filtered).
Behavior Clusters — Authentic User Segments
CLUSTER 01
Sleep Optimizers
Take magnesium glycinate/threonate 1–2 hrs before bed. Primary concern: onset time. Typical switch trigger: no effect by week 2.
28%
CLUSTER 02
Fitness & Recovery
Use magnesium citrate/malate post-workout. Value price-per-serving. High reorder rate. Sensitive to taste/format changes.
22%
CLUSTER 03
Anxiety / Stress Relief
Prefer glycinate form. Often stack with ashwagandha or L-theanine. Most likely to share detailed experience reports.
19%
CLUSTER 04
General Health Maintainers
Long-term daily users. Price-sensitive. Low engagement, high loyalty. Switch only on major price increase (>20%).
16%
CLUSTER 05
Cognitive Enhancement Seekers
Specifically seek L-threonate form. Highly informed (cite clinical studies). Willing to pay 2–3x premium for perceived quality.
10%
CLUSTER 06
Migraine & Pain Management
Use high-dose oxide or citrate. Most likely to consult healthcare provider. Highest side-effect reporting rate (GI issues).
5%
Top Unmet Needs — Market Opportunity Signals
01
"How do I know which form is right for me?"
Mentioned in 12,847 authentic posts (12.6%). Users are confused by glycinate vs. citrate vs. threonate vs. oxide. No brand is effectively solving the form-selection problem. Opportunity: guided recommendation engine or clear educational content with form-to-outcome mapping.
HIGHEST OPPORTUNITY · 12.6% of authentic posts
02
"I can't tell if it's actually working."
8,921 authentic posts (8.8%). Users lack objective feedback on efficacy. Opportunity: biomarker-linked dosing (RBC magnesium testing kits), or app-based symptom tracking paired with product.
HIGH OPPORTUNITY · 8.8% of authentic posts
03
"GI side effects are a dealbreaker."
6,203 authentic posts (6.1%). Primarily affects oxide and citrate users. Glycinate users report this 4x less frequently. Opportunity: slow-release formulation or chelated forms marketed specifically as "gentle" with third-party tolerability data.
MODERATE OPPORTUNITY · 6.1% of authentic posts
04
"I want a combined sleep stack, not 5 separate pills."
4,117 authentic posts (4.0%). Sleep Optimizer cluster frequently mentions taking magnesium + melatonin + L-theanine + glycine separately. Opportunity: all-in-one sleep formula with transparent dosing of each ingredient.
PRODUCT OPPORTUNITY · 4.0% of authentic posts
Patent Intelligence Agent — Case Study
Patent Landscape Analysis:
Curcumin Bioavailability & Delivery Systems
Objective: Map the competitive patent landscape, identify FTO risks, detect prophetic or misleading filings, and find white space for novel delivery technologies.
2,847
Patents Screened
47
Blocking Claims
3
White Spaces Found
8
Fabricated Filings
Patent Filing Density by Technology & Year

Filing intensity across 5 technology areas. Darker = more filings. White space opportunities appear as low-density cells in recent years.

2020
2021
2022
2023
2024
Nanoparticle Enc.
41
58
87
94
62
Lipid Formulation
22
34
45
67
89
Solid Dispersion
38
29
24
18
12
Phytosome / Liposome
14
21
28
39
44
Micelle / Self-emulsify
7
11
15
19
8
Density:
Low → High
White space identified: Micelle / self-emulsifying systems have the lowest filing density and declining activity — despite strong efficacy data in literature. Solid dispersion filings are declining, suggesting saturation or abandonment.
Prophetic & Misleading Filing Detection

The agent cross-references experimental data claimed in patents against published literature, reproducibility databases, and internal consistency checks. Prophetic examples — experiments described in patents that were never actually conducted — are a common defensive practice in biotech patents. They inflate the apparent scope of a filing without supporting data.

⚠
CN1189340B — "Curcumin Nano-Suspension for Cognitive Enhancement"
Fabricated experimental data. Claims 99.2% encapsulation efficiency with a particle size of 12nm. No peer-reviewed literature supports curcumin nanoparticles below 50nm at this efficiency. Cited "in vivo data" references a journal that does not index the cited article. Likely prophetic.
⚠
WO2023/044189 — "Enhanced Curcumin Absorption via Micellar Complex"
Duplicate claims from expired filing. Claims 1–7 are near-identical to expired US8,841,322. Filing appears designed to extend coverage period. Cross-reference shows same applicant with same assignee.
⚠
EP3412890A1 — "Phytosomal Curcumin Composition"
Overly broad prophetic claims. Example 7 claims efficacy across "all neurodegenerative conditions" with a single-dose protocol. No supporting data. Likely filed as a patent mine to create FTO uncertainty for competitors.
⚠
CN116847232A — "Solid Lipid Nanoparticle Curcumin"
Unreproducible results. Claimed 45x bioavailability improvement contradicts pharmacokinetic constraints documented in 23 independent studies. Internal data tables show statistical impossibilities (p-values reported as 0.000).
8 total filings flagged out of 2,847 screened (0.28%). Agent confidence in flagging: High (cross-validated against 3+ independent sources per flag).
Freedom-to-Operate Assessment
2
Clear Paths
Micelle-based delivery and solid dispersion routes have no active blocking patents. Design-around options documented.
1
Requires License
Nanoparticle encapsulation route overlaps with US2024/039221 (Competitor A). Claims 3–7 are potentially blocking. License or design-around needed.
1
Blocked
Phytosome route blocked by Indena S.p.A. master patent (EP1844785B1, expires 2027). No viable design-around within current claims scope.
Agent Recommendation: Pursue micelle/self-emulsifying delivery (clear FTO, low filing density, strong literature support). Nanoparticle route viable with license from Competitor A — estimated licensing cost $50–150K based on comparable deals in the space. Phytosome route not recommended until 2027 patent expiry.